Compare · CDAK vs DFTX
CDAK vs DFTX
Side-by-side comparison of Codiak BioSciences Inc. (CDAK) and Definium Therapeutics Inc. (DFTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CDAK and DFTX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $5.14B, about 41.0x CDAK ($125.2M).
- DFTX has hit the wire 7 times in the past 4 weeks while CDAK has been quiet.
- DFTX has more recent analyst coverage (7 ratings vs 2 for CDAK).
- Company
- Codiak BioSciences Inc.
- Definium Therapeutics Inc.
- Price
- $0.06-53.11%
- $38.20+0.32%
- Market cap
- $125.2M
- $5.14B
- 1M return
- -
- -17.19%
- 1Y return
- -
- +290.79%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 0
- 7
- Recent ratings
- 2
- 7
Codiak BioSciences Inc.
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12, an exosome therapeutic candidates, for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; exoASO-NLRP3 for multiple sclerosis, neuropathy, and neurodegeneration; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics, Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Latest CDAK
- SEC Form SC 13G/A filed by Codiak BioSciences Inc. (Amendment)
- SEC Form 25-NSE filed by Codiak BioSciences Inc.
- SEC Form SC 13G/A filed by Codiak BioSciences Inc. (Amendment)
- Why Bullfrog AI Holdings Shares Are Trading Higher By 73%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
- Why AMC Entertainment Holdings Shares Are Trading Lower By 25%; Here Are 20 Stocks Moving Premarket
- Stocks That Hit 52-Week Lows On Monday
- SEC Form 4 filed by Howze Yalonda
- SEC Form 4 filed by Sathyanarayanan Sriram
- SEC Form 4 filed by Konstantinov Konstantin
- SEC Form 4 filed by Bain Linda
Latest DFTX
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results
- Chief Executive Officer Barrow Robert was granted 40,000 shares and sold $721,733 worth of shares (19,023 units at $37.94) as part of a pre-agreed trading plan, increasing direct ownership by 1% to 1,494,640 units (SEC Form 4) (tax withholding)
- Definium Therapeutics Announces New Employee Inducement Grants
- Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
- BofA Securities initiated coverage on Definium Therapeutics with a new price target
- Definium Therapeutics Announces New Employee Inducement Grants
- Amendment: SEC Form SCHEDULE 13G/A filed by Definium Therapeutics Inc.
- Chief Commercial Officer Wiley Matthew T. was granted 62,500 shares, increasing direct ownership by 36% to 237,133 units (SEC Form 4)
- Chief Medical Officer Karlin Daniel was granted 100,000 shares, increasing direct ownership by 20% to 603,282 units (SEC Form 4)